Behind every GLP-1 provider comparison lurks a structural choice: platforms built on asynchronous questionnaire review versus those requiring a live video visit. It shapes everything — speed, price, and the depth of medicine you receive. We compared the models head-to-head across four dimensions.
Key Takeaways
- Speed: async wins by days — commonly 24–72 hours intake-to-prescription vs. scheduling lead times for video.
- Cost: async's lower clinician-time overhead shows up in lower prices, all else equal.
- Care depth: video wins for complex histories — real-time dialogue catches what checkboxes miss.
- Verdict: simple history → async and save; diabetes, polypharmacy, or GI history → buy the video visit. State law may decide for you anyway.
Round 1: Speed
Async's pipeline — intake, queue, clinician review, e-prescribe — routinely completes in 1–3 days. Video adds scheduling: finding a slot, waiting for it, attending it. For a straightforward patient, async wins this round by 3–7 calendar days. Async, clearly.
Round 2: Cost
A 20-minute live visit costs more clinician time than an async chart review, and pricing reflects it across the market. The gap isn't enormous — and some video-model programs bundle it invisibly — but the structural edge is real. Async on points.
Round 3: Screening and Care Depth
Here the fight reverses. A live clinician probes in real time: the follow-up question about your pancreatitis episode, the medication you forgot until asked twice, the hesitation in your answer about eating history. Checkbox intakes — even conscientious ones — can't chase ambiguity. For a patient with diabetes medications, a long med list, GI history, or psychiatric complexity, that dialogue is where safety lives. Video, decisively, for complex patients; a quality async review is adequate for simple ones.
Round 4: Ongoing Care
Model matters less than culture here — an async platform with fast, substantive portal messaging beats a video platform whose next appointment is three weeks out. Test either the same way: send a clinical question, time the substance of the reply. Draw; judge the provider, not the model.
The Regulatory Referee
Several states require real-time interaction to establish care, so the same national brand may be async in one state and video-first in the next. Your address, entered at intake, may cast the deciding vote in this whole comparison.
Verdicts by Profile
| Profile | Pick | Why |
|---|---|---|
| Healthy, no daily meds, clear-cut BMI | Async | Days faster, cheaper, nothing for video to add |
| Type 2 diabetes / insulin / sulfonylureas | Video | Real-time dose-coordination planning |
| Long medication list or GI history | Video | Dialogue catches interactions checkboxes miss |
| Established patient switching providers | Async | You need continuity, not re-discovery |
| Shift worker / chaotic schedule | Async | No appointment friction at all |
Strong Programs on Each Side
Embody
Injectable semaglutide — $149 first month
Our lead injectable pick: physician-supervised semaglutide with clean flat pricing after the intro month.
Compounded medications are not FDA-approved.
Visit Embody Paid linkCare Bare Rx
Injectable + oral options in intake
Both pathways available depending on clinical review.
Compounded medications are not FDA-approved.
Visit Care Bare Rx Paid linkSesame Care
Brand-name only — Rybelsus and oral Wegovy from $149–$299/mo
Brand-name FDA-approved medications only — the comparison anchor for every compounded price on this site.
Visit Sesame Care Paid linkFinal verdict: async is the right machine for simple cases and the wrong shortcut for complex ones. Know which case you are before the market decides for you.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.